These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21192233)

  • 41. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.
    Cambiano V; Bertagnolio S; Jordan MR; Lundgren JD; Phillips A
    J Infect Dis; 2013 Jun; 207 Suppl 2():S57-62. PubMed ID: 23687290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral therapy programmes in resource limited settings.
    del Rio C; Armstrong W
    BMJ; 2011 Nov; 343():d6853. PubMed ID: 22074712
    [No Abstract]   [Full Text] [Related]  

  • 43. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
    Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
    AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Futility of CD4+ monitoring in HIV-1 patients with CD4+ cell count above 350 cells/μl on suppressive antiretroviral therapy.
    Duncan CJ; Schmid ML; Schwab U; Price DA; Ong E
    AIDS; 2014 Nov; 28(17):2638-9. PubMed ID: 25418545
    [No Abstract]   [Full Text] [Related]  

  • 45. Possible biochemical markers of antiretroviral therapy (ART) failure in resource-constrained areas.
    Onwuliri VA; Ojiako OA; Olukole M; Agbaji A; Carrol L
    Afr J Med Med Sci; 2010 Dec; 39 Suppl():139-44. PubMed ID: 22416656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance.
    Nichols BE; Boucher CA; van de Vijver DA
    J Intern Med; 2011 Dec; 270(6):532-49. PubMed ID: 21929723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries.
    Sigaloff KC; Hamers RL; Menke J; Labib M; Siwale M; Ive P; Botes ME; Kityo C; Mandaliya K; Wellington M; Osibogun A; Geskus RB; Stevens WS; van Vugt M; Rinke de Wit TF;
    Clin Infect Dis; 2012 May; 54 Suppl 4():S294-9. PubMed ID: 22544190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents.
    Winston A; Garvey L; Sabin CA
    AIDS; 2011 Apr; 25(7):1014-5. PubMed ID: 21487256
    [No Abstract]   [Full Text] [Related]  

  • 49. DART points the way for HIV treatment programmes.
    Phillips A; van Oosterhout J
    Lancet; 2010 Jan; 375(9709):96-8. PubMed ID: 20004465
    [No Abstract]   [Full Text] [Related]  

  • 50. Timing of antiretroviral therapy: an immunological perspective.
    Imami N; Hardy G
    J HIV Ther; 2003 Feb; 8(1):15-8. PubMed ID: 12840710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives.
    Harries AD; Zachariah R; van Oosterhout JJ; Reid SD; Hosseinipour MC; Arendt V; Chirwa Z; Jahn A; Schouten EJ; Kamoto K
    Lancet Infect Dis; 2010 Jan; 10(1):60-5. PubMed ID: 20129150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring of antiretroviral therapy in low-resource settings.
    Lawn SD; Bekker LG; Calmy A; Wood R
    Lancet; 2008 Jul; 372(9635):287-8; author reply 289. PubMed ID: 18657697
    [No Abstract]   [Full Text] [Related]  

  • 53. HIV surveillance, public health, and clinical medicine--will the walls come tumbling down?
    Fairchild AL; Bayer R
    N Engl J Med; 2011 Aug; 365(8):685-7. PubMed ID: 21864165
    [No Abstract]   [Full Text] [Related]  

  • 54. [Blood lipid changes at long-term antiretroviral treatment].
    Snopková S; Jarkovský J; Matýsková M; Povolná K; Polák P; Cvanová M; Husa P
    Vnitr Lek; 2011 May; 57(5):463-71. PubMed ID: 21695927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.
    Gilks CF; Crowley S; Ekpini R; Gove S; Perriens J; Souteyrand Y; Sutherland D; Vitoria M; Guerma T; De Cock K
    Lancet; 2006 Aug; 368(9534):505-10. PubMed ID: 16890837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV drugs for treatment, and for prevention.
    Dabis F; Newell ML; Hirschel B
    Lancet; 2010 Jun; 375(9731):2056-7. PubMed ID: 20537377
    [No Abstract]   [Full Text] [Related]  

  • 57. The case for viral load testing in adolescents in resource-limited settings.
    Marcus R; Ferrand RA; Kranzer K; Bekker LG
    J Int AIDS Soc; 2017 Nov; 20 Suppl 7(Suppl 7):. PubMed ID: 29171180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic review of statistically-derived models of immunological response in HIV-infected adults on antiretroviral therapy in Sub-Saharan Africa.
    Sempa JB; Ujeneza EL; Nieuwoudt M
    PLoS One; 2017; 12(2):e0171658. PubMed ID: 28199360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring of antiretroviral therapy in low-resource settings.
    Walensky RP; Freedberg KA; Weinstein MC
    Lancet; 2008 Jul; 372(9635):288; author reply 289. PubMed ID: 18657699
    [No Abstract]   [Full Text] [Related]  

  • 60. Assessment of the effectiveness of antiretroviral treatment among HIV-infected adults: a prospective cohort study in Yunnan Province, 2004-2010.
    Lu L; Ma W; Jia M; Wang L; Guo W; Peng Z; Yu R; Wang N
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):161-2. PubMed ID: 25400262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.